Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards Feb 14, 2020
Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding Feb 14, 2020
Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies Nov 7, 2019
Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update Oct 31, 2019
